Shopping Cart
Remove All
Your shopping cart is currently empty
Lacutoclax
Copy Product Info
😃Good
Catalog No. T79852Cas No. 2291166-56-6
Alias LP-108, LP108
Lacutoclax (LP-108) is an orally active and selective Bcl-2 inhibitor with antitumor activity both in vivo and ex vivo for studies related to lymphoma and leukemia.
Lacutoclax
Copy Product Info😃Good
Catalog No. T79852Alias LP-108, LP108Cas No. 2291166-56-6
Lacutoclax (LP-108) is an orally active and selective Bcl-2 inhibitor with antitumor activity both in vivo and ex vivo for studies related to lymphoma and leukemia.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $288 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Appearance:Solid
Color:Yellow
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Lacutoclax (LP-108) is an orally active and selective Bcl-2 inhibitor with antitumor activity both in vivo and ex vivo for studies related to lymphoma and leukemia. |
| Targets&IC50 | H1963 cells: 0.45 μM, H146 cells: 0.23 μM |
| In vitro | In small cell lung cancer (SCLC) cell lines such as H146 and H1963, treatment with the active metabolite Lacutoclax (0.1–10 μM for 24–72 hours)inhibited cell proliferation, with IC₅₀ values of 0.23 μM and 0.45 μM, respectively. The treatment induced apoptosis as evidenced by caspase activation, PARP cleavage, and increased Annexin V-positive cells, indicating a mitochondrial pathway–dependent mechanism[1]. |
| In vivo | In NOD/SCID mice bearing H146 or H1963 xenografts, intravenous administration of Lacutoclax (25–100 mg/kg, once daily for 10 consecutive days) led to dose-dependent tumor growth inhibition. At 100 mg/kg, some tumors completely regressed. Treated mice maintained stable body weight with no significant toxicity, demonstrating strong antitumor efficacy and good tolerability[1]. |
| Synonyms | LP-108, LP108 |
| Molecular Weight | 923.52 |
| Formula | C48H55ClN8O7S |
| Cas No. | 2291166-56-6 |
| Smiles | C(NS(=O)(=O)C1=CC(N(=O)=O)=C(NCC2CCOCC2)C=C1)(=O)C3=C(N4C5=C(NC=6C(=C5)C=CN6)O[C@H](C)C4)C=C(C=C3)N7CCN(CC8=C(CC(C)(C)CC8)C9=CC=C(Cl)C=C9)CC7 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Lacutoclax | purchase Lacutoclax | Lacutoclax cost | order Lacutoclax | Lacutoclax chemical structure | Lacutoclax in vivo | Lacutoclax in vitro | Lacutoclax formula | Lacutoclax molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.